Tegobuvir antiviral activity in a HeLa cell replicon model
Cell-based study · GT 1b (Con-1) replicon in the the HeLa cell line [1]
Tegobuvir was added to plates containing a HeLa cell replicon model and was reported to be vastly less potent against this replicon.
| Endpoint | Reported result | Reference |
|---|---|---|
| antiviral effect | EC50 EC50>10 µM | [1] |
Literature-Reported Treatment Conditions
- Exposure duration
- 72 hours
- Method
- subsequent addition to cell plates
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: Tegobuvir
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Replicon EC50 determinations (S20, S21, S22, S23); Results > NS5B doublet formation correlates with TGV potency (S91)
antiviral effect: antiviral effect; comparator: untreated cells — Methods > Replicon EC50 determinations (S23); Results > NS5B doublet formation correlates with TGV potency (S91)